HCAR2 and inflammatory bowel disease: Overall, colon-targeted delivery of tCA potentiates the anti-colitic activity of tCA and elicits anti-colitic effects superior to SSZ, a current anti-IBD drug, at least partly, by effectively activating GPR109A in the inflamed colons of rats.